Genmab presents "encouraging" data for cervical cancer candidate
![Photo: Joost Melis / Genmab / PR](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/article13294738.ece/ALTERNATES/schema-16_9/doc7hm8em9isg67744bbpn.jpg)
Genmab and its partner Seagen have presented interim data from a study of the drug tisotumab vedotin in combination therapy with the treatment of recurrent or metastatic cervical cancer.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.